Sonnet Biotherapeutics Holdings Inc
SONN4.082USD
+0.881+27.55%
Market hours （ET）Quotes delayed by 15 min
13.60MMarket Cap
LossP/E TTM
More Details of Sonnet Biotherapeutics Holdings Inc Company
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Sonnet Biotherapeutics Holdings Inc Info
Ticker SymbolSONN
Company nameSonnet Biotherapeutics Holdings Inc
IPO dateJul 27, 2005
CEOMr. Raghu Rao
Number of employees13
Security typeOrdinary Share
Fiscal year-endJul 27
Address100 Overlook Center
CityPRINCETON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code08540
Phone16093752227
Websitehttps://www.sonnetbio.com/
Ticker SymbolSONN
IPO dateJul 27, 2005
CEOMr. Raghu Rao
Company Executives of Sonnet Biotherapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raghu Rao
Mr. Raghu Rao
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
2.36K
--
Dr. John K. Cini, Ph.D.
Dr. John K. Cini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
2.12K
--
Ms. Susan Dexter
Ms. Susan Dexter
Chief Technical Officer
Chief Technical Officer
1.64K
--
Dr. Richard T. Kenney, M.D.
Dr. Richard T. Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
1.37K
--
Mr. Nailesh Bhatt
Mr. Nailesh Bhatt
Independent Director
Independent Director
547.00
--
Mr. Albert D. Dyrness
Mr. Albert D. Dyrness
Independent Director
Independent Director
537.00
--
Ms. Lori Mcneill
Ms. Lori Mcneill
Independent Director
Independent Director
394.00
--
Mr. Donald J. Griffith, CPA
Mr. Donald J. Griffith, CPA
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Jenene Thomas
Mr. Jenene Thomas
IR Contact Officer
IR Contact Officer
--
--
Dr. Stephen Mcandrew, Ph.D.
Dr. Stephen Mcandrew, Ph.D.
President and Chief Business Officer
President and Chief Business Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Raghu Rao
Mr. Raghu Rao
Interim Chief Executive Officer, Director
Interim Chief Executive Officer, Director
2.36K
--
Dr. John K. Cini, Ph.D.
Dr. John K. Cini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
2.12K
--
Ms. Susan Dexter
Ms. Susan Dexter
Chief Technical Officer
Chief Technical Officer
1.64K
--
Dr. Richard T. Kenney, M.D.
Dr. Richard T. Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
1.37K
--
Mr. Nailesh Bhatt
Mr. Nailesh Bhatt
Independent Director
Independent Director
547.00
--
Mr. Albert D. Dyrness
Mr. Albert D. Dyrness
Independent Director
Independent Director
537.00
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Republic Digital Opportunistic Digital Assets Master Fund Ltd
3.67%
MMCAP Asset Management
1.89%
The Vanguard Group, Inc.
0.89%
BIT Capital GmbH
0.68%
Geode Capital Management, L.L.C.
0.35%
Other
92.52%
Shareholders
Shareholders
Proportion
Republic Digital Opportunistic Digital Assets Master Fund Ltd
3.67%
MMCAP Asset Management
1.89%
The Vanguard Group, Inc.
0.89%
BIT Capital GmbH
0.68%
Geode Capital Management, L.L.C.
0.35%
Other
92.52%
Shareholder Types
Shareholders
Proportion
Corporation
3.67%
Hedge Fund
1.91%
Investment Advisor
1.88%
Investment Advisor/Hedge Fund
0.35%
Individual Investor
0.22%
Venture Capital
0.19%
Other
91.77%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
27
306.73K
4.33%
-485.44K
2025Q2
42
217.03K
3.73%
-164.88K
2025Q1
49
216.94K
6.86%
-38.71K
2024Q4
47
142.46K
4.65%
-26.07K
2024Q3
47
41.15K
2.68%
-136.57K
2024Q2
52
111.48K
15.39%
+15.28K
2024Q1
53
47.27K
6.49%
-61.26K
2023Q4
55
63.31K
18.25%
-49.43K
2023Q3
54
43.80K
20.23%
-50.04K
2023Q2
52
54.80K
26.54%
-1.94K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Republic Digital Opportunistic Digital Assets Master Fund Ltd
260.00K
3.81%
+260.00K
--
Jul 14, 2025
MMCAP Asset Management
133.59K
1.96%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
28.10K
0.41%
--
--
Aug 31, 2025
BIT Capital GmbH
428.79K
6.28%
+234.14K
+120.28%
Aug 31, 2025
Geode Capital Management, L.L.C.
24.89K
0.36%
+87.00
+0.35%
Jun 30, 2025
XTX Markets LLC
13.67K
0.2%
+13.67K
--
Jun 30, 2025
UBS Financial Services, Inc.
6.66K
0.1%
+6.52K
+4622.70%
Jun 30, 2025
McAndrew (Stephen J. Ph.D.)
6.45K
0.09%
+6.00K
+1345.29%
Jul 11, 2025
Creand Wealth Management
4.69K
0.07%
--
--
Apr 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Aug 31, 2023
Merger
22→1
Aug 31, 2023
Merger
22→1
Date
Type
Ratio
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Sep 12, 2024
Merger
8→1
Aug 31, 2023
Merger
22→1
Aug 31, 2023
Merger
22→1
Aug 31, 2023
Merger
22→1
Aug 31, 2023
Merger
22→1
Sep 16, 2022
Merger
14→1
Sep 16, 2022
Merger
14→1
View more
